CorMedix Inc. (NYSEAMERICAN:CRMD) dropped 17.7% on Thursday . The company traded as low as $0.92 and last traded at $0.93. Approximately 2,986,047 shares traded hands during trading, an increase of 9% from the average daily volume of 2,750,527 shares. The stock had previously closed at $1.13.
CRMD has been the subject of a number of research analyst reports. Zacks Investment Research cut CorMedix from a “hold” rating to a “sell” rating in a research note on Tuesday, September 25th. HC Wainwright set a $3.00 price target on CorMedix and gave the company a “buy” rating in a research note on Wednesday, August 15th.
CorMedix (NYSEAMERICAN:CRMD) last released its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.10 million.
COPYRIGHT VIOLATION WARNING: “CorMedix (CRMD) Shares Down 17.7%” was originally posted by BBNS and is the property of of BBNS. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://baseballnewssource.com/2018/11/16/cormedix-crmd-shares-down-17-7/2998734.html.
CorMedix Company Profile (NYSEAMERICAN:CRMD)
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Further Reading: What is a Swap?
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.